CECC to expand eligibility for receiving preventative monoclonal antibody medication targeting SARS-CoV-2 and adjust related recommendations based on dominant strains and effectiveness of medication

On April 7, the Central Epidemic Command Center (CECC) announced that, to maximize the benefits of Evusheld and provide enhanced protection for high-risk groups when epidemic prevention measures are being loosened, it will expand eligibility for receiving Evusheld. This eligibility expansion will allow malignant tumor patients requiring intensive treatments, organ transplant patients (including blood stem cell transplant patients) with catastrophic illness cards, and patients with systemic autoimmune syndrome who require lifelong treatment and have catastrophic illness cards to be eligible for receiving Evusheld. Additionally, the conditions for using the medication will be changed from no infection with SARS-CoV-2 within six months to no infection with the virus within three months in order to be in line with the new eligibility.